Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
231 participants
INTERVENTIONAL
2002-10-31
2003-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients
NCT00300963
Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia
NCT00103727
Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00056498
A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia
NCT00253136
Identification and Treatment of the Liability to Develop Schizophrenia
NCT00305474
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
talnetant
risperidone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients whose condition is due to the direct physiological effects of a substances (e.g., drug abuse) or a general medical condition.
* Patients with a history of autistic disorder or another pervasive developmental disorder.
* Patients with epilepsy or a history of seizures requiring treatment.
* Patients who are excluded from taking the drug risperidone.
* Patients who pose a current serious suicidal or homicidal risk.
* Patients who are adequately stabilized on their treatment.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials, MD
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Clinical Trial Call Center
Scottsdale, Arizona, United States
GSK Clinical Trial Call Center
Cerritos, California, United States
GSK Clinical Trial Call Center
Chula Vista, California, United States
GSK Clinical Trial Call Center
Garden Grove, California, United States
GSK Clinical Trial Call Center
Orange, California, United States
GSK Clinical Trial Call Center
Pico Rivera, California, United States
GSK Clinical Trial Call Center
Rosemead, California, United States
GSK Clinical Trial Call Center
Sacramento, California, United States
GSK Clinical Trial Call Center
San Diego, California, United States
GSK Clinical Trial Call Center
San Diego, California, United States
GSK Clinical Trial Call Center
New Britain, Connecticut, United States
GSK Clinical Trial Call Center
New Haven, Connecticut, United States
GSK Clinical Trial Call Center
Washington D.C., District of Columbia, United States
GSK Clinical Trial Call Center
North Miami, Florida, United States
GSK Clinical Trial Call Center
Tampa, Florida, United States
GSK Clinical Trial Call Center
Winter Park, Florida, United States
GSK Clinical Trial Call Center
Hoffman Estates, Illinois, United States
GSK Clinical Trial Call Center
Greenwood, Indiana, United States
GSK Clinical Trial Call Center
Shreveport, Louisiana, United States
GSK Clinical Trial Call Center
Clementon, New Jersey, United States
GSK Clinical Trial Call Center
Hollis, New York, United States
GSK Clinical Trial Call Center
Butner, North Carolina, United States
GSK Clinical Trial Call Center
Raleigh, North Carolina, United States
GSK Clinical Trial Call Center
Cincinnati, Ohio, United States
GSK Clinical Trial Call Center
Cleveland, Ohio, United States
GSK Clinical Trial Call Center
Norman, Oklahoma, United States
GSK Clinical Trial Call Center
Oklahoma City, Oklahoma, United States
GSK Clinical Trial Call Center
Nashville, Tennessee, United States
GSK Clinical Trial Call Center
Austin, Texas, United States
GSK Clinical Trial Call Center
Bellaire, Texas, United States
GSK Clinical Trial Call Center
Terrell, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SB223412/078
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.